Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • Alcohol addiction
  • R&D / Pipeline
  • Product KT-110
  • Partners / Investors
  • Business strategy
  • News
  • Contact us

Kinnov Therapeutics CEO

20+ years expertise in Med Chem.
Founder and Manager of Greenpharma
Is author of more than 50 scientific publications and 20 patents.

Dr Philippe BERNARD
kinnov February 8, 2020September 14, 2023 equipe
  • ← Kinnov Therapeutics raised 2.5 M€ for Phase 2 study of KT-110 on alcohol addiction
  • Emmanuel de RIVOIRE →

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Alcohol addiction
  • Business strategy
  • Company
  • Contact us
  • Home
  • Partners / Investors
  • Preclinical trials
  • Product KT-110
  • R&D / Pipeline

Copyright 2020 - Kinnov Therapeutics